The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 119)
Clinical Intervention Awards, 2012
Apomorphine is an under-utilized medication in Parkinson's disease (PD). Despite its strong efficacy as a rescue medication for intermittent "off" episodes in PD and its rapid onset of action, the Apokyn injection of apomorphine can be painful and patients can resist use until the latest stages of PD. Additionally, physicians find the dose initiation cumbersome. Eliminating som...
Rapid Response Innovation Awards, 2012
Enzymatic Degradation of Brain Complex Gangliosides to Increase Endogenous GM1 Levels: Potential Neuroprotective/Neurorestorative Therapy for Parkinson's disease
Pre-clinical studies and clinical studies with GM1 ganglioside in Parkinson's disease patients suggest potential symptomatic and disease modifying effects of GM1 on Parkinson's disease. However, an alternative therapeutic approach to administering exogenous GM1 might be to enhance endogenous levels of GM1 in the brain. One potential way to do this is by administering sialidas...
Researchers: Jay S. Schneider, PhD
Dyskinesia LEAPS, 2012
Dyskinesia is a term used to describe involuntary movements that develop as side effects of dopamine drugs used to treat Parkinson's disease. Dyskinesias are frequent and disabling to many patients. They can interrupt smooth coordinated movements, affect communication and disrupt activities of daily living. Currently, among medications to treat dyskinesia, only amantadine is e...
Target Validation, 2012
Parkinson's disease is associated with changes in the electrical activity of nerve cells in the basal ganglia and thalamus, including the emergence of abnormal burst discharges, due in part to dysfunction of a specific type of ion channel on nerve cell membranes, called T-type calcium channel. We hypothesize that abnormal bursting contributes to the development of parkinsonia...
Researchers: Thomas Wichmann, MD
Dyskinesia Challenge, 2012
Promising Outcomes of Original Grant:
In Parkinson's disease, dopamine-producing neurons degenerate, leading to a lack of dopamine in the brain. This leads to profound changes in the cells which are geared to respond to the dopamine. We have found that a protein, CK2, modulates the efficiency of dopamine signaling. We generated a pre-clinical model where CK2 is deleted in dopamine responsive neuron...
Researchers: Heike Rebholz, PhD